Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.33963/KP.15302 http://scihub22266oqcxt.onion/10.33963/KP.15302 32336069!ä!32336069 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kardiol+Pol 2020 ; 78 (4): 278-283 Nephropedia Template TP {{tp|p=32336069|t=2020. What should a cardiologist know about coronavirus disease 2019?|pdf=|usr=}}{{32336069}} gab.com Text What should a cardiologist know about coronavirus disease 2019 JO: Kardiol Pol http://www.kidney.de/pget.php?&tw=1&pmid=32336069 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) is the cause of coronavirus disease 2019 (COVID?19). The most common symptoms of COVID?19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID?19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum C?reactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and D?dimer concentrations (36%-46.4%). Among comorbidities in patients with COVID?19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID?19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID?19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated N?terminal pro-B?type natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the life?threatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID?19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID?19 symptoms, possible clinical manifestations, complications, and recommended treatment. Twit Text FOAVip What should a cardiologist know about coronavirus disease 2019 ????Kardiol Pol http://www.kidney.de/pget.php?&tw=1&pmid=32336069 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32336069 #FOAvip English Wikipedia <ref>{{Cite pmid|32336069}}</ref> What should a cardiologist know about coronavirus disease 2019? #MMPMID32336069 Slawinski G; Lewicka E Kardiol Pol 2020[Apr]; 78 (4): 278-283 PMID32336069show ga Severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) is the cause of coronavirus disease 2019 (COVID?19). The most common symptoms of COVID?19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID?19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum C?reactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and D?dimer concentrations (36%-46.4%). Among comorbidities in patients with COVID?19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID?19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID?19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated N?terminal pro-B?type natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the life?threatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID?19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID?19 symptoms, possible clinical manifestations, complications, and recommended treatment. |Angiotensin Receptor Antagonists/adverse effects/therapeutic use[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use[MESH] |Antiviral Agents/adverse effects/therapeutic use[MESH] |COVID-19[MESH] |Cardiology[MESH] |Cardiovascular Diseases/drug therapy/*epidemiology/etiology[MESH] |Comorbidity[MESH] |Coronavirus Infections/*diagnosis/drug therapy/*epidemiology/metabolism[MESH] |Cost of Illness[MESH] |Critical Care[MESH] |Diabetes Mellitus/epidemiology[MESH] |Humans[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Pneumonia, Viral/*diagnosis/drug therapy/*epidemiology/metabolism[MESH] |Professional Practice[MESH] |Prognosis[MESH]What should a cardiologist know about coronavirus disease 2019?(epmc).pdf DeepDyve Pubget Overpricing